Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies

Eur J Cancer. 2017 Aug:81:135-137. doi: 10.1016/j.ejca.2017.05.017.
No abstract available

Keywords: Anti-programmed death 1; Anti-programmed death ligand 1; Emergent adverse event; Eosinophilia; Immune-related adverse event.

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Administration, Intravenous
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / immunology
  • Eosinophilia / chemically induced*
  • Eosinophilia / epidemiology
  • Eosinophilia / immunology
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Melanoma / epidemiology
  • Melanoma / pathology
  • Middle Aged
  • Nivolumab
  • Pharmacovigilance
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / epidemiology
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • durvalumab
  • Nivolumab
  • pembrolizumab